started · updated
Amgen reports positive Phase 3 trial results for Sjögren’s drug
Amgen has announced positive results from its Phase 3 OASIZ-301 clinical trial evaluating dazodalibep, an experimental CD40L antagonist, for the treatment of moderate to severe Sjögren’s syndrome. The randomized, placebo-controlled study met its primary endpoints after 48 weeks of treatment.
Two dosing regimens were tested: a 1,500 mg dose administered every four weeks and a 3,000 mg dose every twelve weeks. The 1,500 mg regimen reduced systemic disease activity by an average of 5.6 points compared to 3.8 points for the placebo group. The 3,000 mg regimen showed a 5.2-point reduction. Additionally, the monthly 1,500 mg dose significantly improved patient-reported dryness symptoms.
Amgen reported that treatment benefits were observable as early as week four and were maintained through week 48. The company plans to present full data at the ACR Convergence 2026 meeting. Despite the clinical success, Amgen shares saw a slight decline of 0.77% following the announcement.
Entities
ACR Convergence 2026 · American College of Rheumatology · Amgen · Amgen Inc. · European Alliance of Associations for Rheumatology · Sjögren’s syndrome · dazodalibep